Pulmonx (LUNG) vs Nyxoah SA (NYXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pulmonx (LUNG) has outperformed Nyxoah SA (NYXH) over the past year, gaining 6.4% versus a loss of 78.7%. Over five years, NYXH leads with a -94.7% price change compared with -95.4% for LUNG. Nyxoah SA is the larger company by market cap ($138.5 million vs $79.0 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUNG | NYXH |
|---|---|---|
| Share price | $1.84 | $1.36 |
| Market cap | $79.02M | $138.50M |
| 1-day change | +1.66% | +0.74% |
| YTD return | -16.74% | -70.43% |
| 1-year return | +6.36% | -78.72% |
| 5-year return | -95.38% | -94.67% |
| EPS (TTM) | $-1.15 | $-2.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.89 | $6.60 |
| 52-week low | $1.13 | $1.26 |
| Distance from 52-week high | -36.33% | -79.39% |
| Analyst consensus | none | none |
| Avg. price target upside | +84.78% | +208.82% |
| Average volume | 481.56K | 276.69K |
| Shares outstanding | 42.95M | 101.84M |
| Employees | 296 | 153 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed NYXH by 85.1 percentage points over the past year.
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
About Nyxoah SA
NYXH stock →Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
Health Care · Medical/Dental Instruments · 153 employees
LUNG vs NYXH FAQ
Which is bigger, Pulmonx or Nyxoah SA?
Nyxoah SA (NYXH) is larger, with a market capitalization of $138.50M compared with $79.02M for Pulmonx (LUNG).
Which stock has performed better over the past year, LUNG or NYXH?
LUNG returned +6.36% over the past 12 months, compared with -78.72% for NYXH (price return, excluding dividends). Past performance does not predict future results.
Are Pulmonx and Nyxoah SA in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.